Navigation Links
Norgen Biotek Corp. Launches Four New Kits for the Purification of RNA and DNA from Plants and Fungi
Date:7/18/2008

THOROLD, ON, July 18 /PRNewswire/ - Norgen Biotek Corp., an innovative Canadian biotechnology company focusing primarily on advancing powerful tools for RNA, DNA and protein purifications, today announced the expansion of its product offerings by launching four new kits geared towards the isolation of RNA and DNA from plants and fungi for research and diagnostic applications. In response to customer demands and emerging needs Norgen developed this new line of kits which are all available in spin-column formats as well as in 96-well plate formats for high throughput applications. The new kits include:

1- The Plant/Fungi RNA Purification Kit:

2- The Plant/Fungi DNA Isolation Kit:

These kits provide rapid methods for the isolation and purification of total RNA and genomic DNA respectively from a wide range of plant and filamentous fungal species. The Plant/Fungi RNA Purification Kit isolates all sizes of RNA, from large mRNA and ribosomal RNA down to microRNA. The purified RNA is of the highest integrity, and can be used in a number of downstream applications including Real-Time PCR, reverse transcription PCR, Northern blotting, RNase protection and primer extension, and expression array assays. With the Plant/Fungi DNA Isolation Kit total DNA is isolated including genomic DNA, mitochondrial DNA and chloroplast DNA. The purified DNA can be used in a number of downstream applications including Real-Time PCR, Southern blotting and sequencing.

3- The Plant RNA/DNA Purification Kit:

This novel kit enables scientists to isolate total RNA, including microRNA, and genomic DNA simultaneously from a single plant sample. This approach cuts down on the number of extractions during the screening for plant pathogens.

4- The Direct Fungal DNA Isolation Kit:

This kit allows for the rapid isolation and purification of genomic DNA from the fungi found on the surface of symptomatic plant samples. A major benefit of this kit is that it does not require the use of physical homogenization steps to isolate the fungal DNA, which are often time consuming and tedious procedures. While a mortar and pestle, a rotor-stator homogenizer or bead mills associated with liquid nitrogen may enhance the DNA extraction yield, they are not suitable methods for use in the analysis of large numbers of samples, and in the area of pathogen diagnosis simple and convenient sample preparation steps are a critical factor in supporting high throughput analysis. The procedure yields sufficient fungal DNA to be used in a number of downstream applications including Real-Time PCR, sequencing, Southern blotting and SNP analysis and the total procedure can be completed less than 60 minutes.

"Our new line of kits to isolate RNA and DNA from plants represents an exciting addition to our high quality novel products. We listened to the demands of our customers and developed kits geared towards current market needs. We are confident that these kits will enable researchers in all areas of plant research, particularly in plant diagnostics" said Dr. Haj-Ahmad, President & CEO of Norgen Biotek.

About Norgen Biotek Corp.

-------------------------

Norgen is an innovative, rapidly growing privately-held fully integrated biotechnology company. We conduct R&D, manufacture and market a variety of commercial sample preparation products derived from our proprietary technology. This technology is used in protein, RNA and DNA purification, isolation, and concentration and clean-up kits. Norgen is actively working on the adoption of this enabling technology into the diagnostic market as well as industrial scale applications. We are seeking suitable channels to market partners. Additional information is available on the company's website: http://www.norgenbiotek.com


'/>"/>
SOURCE Norgen Biotek Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
3. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
4. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
5. MAKO Surgical Corp. Files Registration Statement for Initial Public Offering of Common Stock
6. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
7. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
8. Helix BioPharma Corp. announces fiscal 2007 results
9. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
10. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
11. Helix BioPharma Corp. announces management changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):